Dunedin-based probiotics firm is forecasting a significant loss on the back of declining revenues, business generation expenses and the global impacts of covid on its core markets.
With low nicotine requirements on the cards, tobacco companies will have to rethink their NZ market.
Ebos' medical devices businesses have about $70 million in annual revenue while LifeHealthcare has about A$326m.
Ebos will pay about A$1.17 billion for the LifeHealthcare business in New Zealand, Australia and Asia.